Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
NCT02090673
·
clinicaltrials.gov ↗
COMPLETED
Status
1711
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes Mellitus Type 2
Interventions
DRUG:
Exenatide
Sponsor
AstraZeneca